Comparative Pharmacology
Head-to-head clinical analysis: OLOPATADINE HYDROCHLORIDE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLOPATADINE HYDROCHLORIDE versus XYZAL.
OLOPATADINE HYDROCHLORIDE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine